Topic

diagnostics

13 articles on diagnostics in longevity medicine. View all news →

TimePie x Frost & Sullivan 2026 Global Longevity Medicine Implementation Guide Kick Off

Longevity Medicine Implementation: How to Judge Clinic Delivery in 2026

A buyer guide to longevity medicine implementation: how to judge clinic delivery, governance, AI claims, incidental findings, and follow-up before you pay.

Neko Health Scan

Neko Health Cost in 2026: £299 UK Scan, NYC Opening, and Follow-Up Questions

Neko lists its UK scan at £299 and plans to open in New York on September 24, 2026, but no US price is public. Here is what the scan includes and what to verify.

Business Insider: I took a $12K Silicon Valley longevity exam

Human Longevity Exam Cost: What a $12K HLI Assessment Really Buys (2026)

A buyer guide to Human Longevity exam cost, HLI-style diagnostics, genetics, full-body imaging, and the follow-up questions to ask before paying.

American College of Radiology: Statement on Screening Total Body MRI

Longevity Clinic Follow-Up Plan: What Happens After Testing? (2026)

A practical guide to the follow-up plan after a longevity assessment: clinical ownership, abnormal findings, referrals, retesting, records, costs, and red flags.

Mayo Clinic Executive Health Program

Executive Health vs Longevity Clinic: Which Preventive Health Path Should You Choose in 2026?

A decision framework for choosing executive health, concierge prevention, or a longevity clinic in 2026 based on risk profile, diagnostics, follow-up, budget, and red flags.

JAMA: U.S. POINTER multidomain lifestyle intervention trial

Cognitive Decline and Longevity Clinics: Tests, Evidence, and Red Flags (2026)

A cautious 2026 guide to cognitive decline, longevity clinics, brain-health tests, lifestyle evidence, referral pathways, and red flags.

cognitive decline longevity clinics brain health longevity clinics
2026 ACC/AHA Guideline for the Management of Dyslipidemia

Longevity Clinic Blood Test Panels: Useful Biomarkers and Red Flags (2026)

A buyer guide to longevity blood panels: decision-relevant tests, selective add-ons, exploratory biomarkers, repeat-testing logic, and commercial red flags.

longevity clinic blood test panel biomarkers executive health
British Journal of Sports Medicine: Cardiorespiratory Fitness and Health Outcomes

VO2 Max Testing at Longevity Clinics: CPET, Safety, and What the Evidence Shows

VO2 max is one of the better-supported longevity metrics, but the value depends on testing quality, medical screening, and a plan after the number.

A Framework for an Effective Healthy Longevity Clinic

What Should a Longevity Health Assessment Include in 2026?

A practical buyer’s guide to longevity health assessments: biomarkers, imaging, genetics, fitness testing, costs, and the questions to ask before booking.

longevity health assessment executive health diagnostics
Whole-body MRI for opportunistic cancer detection in asymptomatic individuals: a systematic review and meta-analysis

Full-Body MRI at Longevity Clinics: Cost, False Positives, and Smarter Alternatives (2026)

A buyer's guide to full-body MRI at longevity clinics: what it can detect, what it misses, real cost models, false positives, and safer alternatives.

BBC Worklife

Longevity Treatments in 2026: What BBC Experts Say Is Proven, Uncertain, or Self-Experimentation

BBC reporting shows a market ranging from ordinary prevention to expensive tests and experimental treatments. This guide separates documented offers from proven health benefit.

Biograph memberships

Biograph Core vs Black in 2026: $7,500 vs $15,000 and the Follow-Up Included

A current comparison of Biograph Core and Black: price, tests, clinical touchpoints, exclusions, and the questions to ask before paying for a diagnostic membership.

NAD+ precursor supplementation in human ageing: clinical evidence and challenges

NAD+ in Human Ageing: The 2025 Nature Metabolism Review, Updated for 2026

The Nature Metabolism review found sparse human tissue data and limited clinical efficacy. Three 2026 studies add narrow signals, but do not establish NAD+ interventions as general longevity treatments.